Unknown

Dataset Information

0

Reply to: "Progressive cholangiopathy in COVID-19 patients: Other possible diagnoses than ketamine-induced cholangiopathy should be considered".

ABSTRACT:

SUBMITTER: Mallet V 

PROVIDER: S-EPMC8223115 | biostudies-literature |

REPOSITORIES: biostudies-literature

Json Xml

Similar Datasets

Unknown Progressive cholangiopathy in COVID-19 patients: Other possible diagnoses than ketamine-induced cholangiopathy should be considered.
| S-EPMC7977066 | biostudies-literature
Unknown Intravenous ketamine and progressive cholangiopathy in COVID-19 patients.
| S-EPMC7893247 | biostudies-literature
Unknown COVID-19-Related Cholangiopathy: Histological Findings.
| S-EPMC11354040 | biostudies-literature
Unknown Critical Illness Cholangiopathy in COVID-19 Long-haulers.
| S-EPMC9123802 | biostudies-literature
Unknown Post-COVID-19 cholangiopathy: Current understanding and management options.
| S-EPMC10277943 | biostudies-literature
Unknown Authors' reply: Hypoalbuminemia in COVID-19.
| S-EPMC8662292 | biostudies-literature
Unknown Cancer and COVID-19 - Authors' reply.
| S-EPMC7544437 | biostudies-literature
Unknown COVID-19-associated cholangiopathy: What is left after the virus has gone?
| S-EPMC9350171 | biostudies-literature
Unknown COVID-19 in pregnant women - Authors' reply.
| S-EPMC7195406 | biostudies-literature
Unknown Mavrilimumab for severe COVID-19 - Authors' reply.
| S-EPMC7837188 | biostudies-literature